Início › Câncer de Ovário › Maryland
Ensaios clínicos de Câncer de Ovário em Maryland
40 estudos para Câncer de Ovário estão buscando participantes em locais em Maryland.
Cidades em Maryland
Texto oficial do estudo (Inglês)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Walter Reed National Military Medical Center, Bethesda
RecrutandoVoluntários saudáveis bem-vindos
Idades de 45 a 75 · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT06995898Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- University of Maryland/Greenebaum Cancer Center, Baltimore
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- e mais 1
RecrutandoFase 2
Todas as idades · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT05564377Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 1
Idades de 18 a 120 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04847063Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 2
Idades de 18 a 72 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT01174121Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
RecrutandoEstudo observacional
Idades 3 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT01441089Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
- National Institutes of Health Clinical Center, Bethesda
RecrutandoEstudo observacional
Idades de 2 a 100 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT01950572Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 1
Idades de 18 a 120 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06885697A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Baltimore
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 1 de out. de 2026 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Maryland, Baltimore /ID# 275308, Baltimore
- Holy Cross Hospital /ID# 275872, Silver Spring
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT06890338Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 2
Idades de 18 a 72 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT03412877A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital Of Baltimore, Baltimore
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- United Theranostics, Glen Burnie
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213791A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Maryland Oncology Hematology (MOH) ( Site 8002), Columbia
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 17 de set. de 2026 · NCT07318558Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Holy Cross Hospital, Silver Spring
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 15 de set. de 2026 · NCT07214779A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Greater Baltimore Medical Center, Baltimore
RecrutandoFase 2
Idades de 18 a 99 · Mulheres · Atualizado em 15 de set. de 2026 · NCT07023627A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT05123482Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Greater Baltimore Medical Center, Towson
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 9 de set. de 2026 · NCT07225270Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Holy Cross Hospital, Silver Spring
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 26 de ago. de 2026 · NCT05281471Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 1/2
Idades de 18 a 72 · Todos os sexos · Atualizado em 13 de ago. de 2026 · NCT02830724A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Christiana Care - Union Hospital, Elkton
Recrutando
Idades de 35 a 50 · Mulheres · Atualizado em 7 de ago. de 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Christiana Care - Union Hospital, Elkton
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT04657068A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- The John Hopkins Hospital, Baltimore
- Maryland Oncology Hematology- Columbia, Rockville
RecrutandoFase 2
Idades 8 e acima · Todos os sexos · Atualizado em 27 de jul. de 2026 · NCT05503797Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
- University of Maryland, Baltimore
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 14 de jul. de 2026 · NCT05804370Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Greater Baltimore Medical Center, Towson
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 2 de jul. de 2026 · NCT06819007EXoPERT EMERALD Clinical Study
- John Hopkins University, Baltimore
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades 45 e acima · Todos os sexos · Atualizado em 1 de jul. de 2026 · NCT07186296Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA11-0, Bethesda
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de mai. de 2026 · NCT0695308918F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 2
Idades de 18 a 120 · Todos os sexos · Atualizado em 19 de mai. de 2026 · NCT06503146Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 11 de mar. de 2026 · NCT03968406A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT06778863CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Maryland Oncology Hematology, P.A., Annapolis
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 23 de dez. de 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- e mais 1
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 27 de out. de 2025 · NCT06617923Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
- Anne Arundel Health System, Annapolis
- Johns Hopkins University School of Medicine, Baltimore
RecrutandoEstudo observacional
Idades 30 e acima · Mulheres · Atualizado em 16 de set. de 2025 · NCT04794322A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- Johns Hopkins, Baltimore
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de mai. de 2025 · NCT04503265BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Holy Cross Hospital, Silver Spring
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 7 de mar. de 2025 · NCT04196257Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.